Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with dexamethasone may kill more cancer cells.

PURPOSE: This phase II trial is studying how well giving bortezomib together with dexamethasone works in treating patients with multiple myeloma that has relapsed or has not responded to treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sparrow Regional Cancer Center
• Treatments: BB 1101; Bortezomib; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of multiple myeloma

• Refractory or relapsed disease meeting the following criteria:

• Primary refractory disease and first-line relapsing disease

• Progressive disease after last therapy

PATIENT CHARACTERISTICS:

• ECOG performance status 0-2

• Life expectancy > 3 months

• Platelet count ≥ 50,000/mm³ (≥ 30,000/mm³ for patients with significant bone marrow involvement)

• Transfusions allowed

• Hemoglobin ≥ 7.5 g/dL

• Absolute neutrophil count ≥ 750/mm³

• Serum calcium < 14 mg/dL

• AST and ALT < 2.5 times upper limit of normal

• Creatinine clearance ≥ 30 mL/min

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• No peripheral neuropathy ≥ grade 2 within the past 14 days

• No hypersensitivity to boron or mannitol

• No cardiovascular complications, including any of the following:

• Myocardial infarction within the past 6 months

• New York Heart Association class III-IV heart failure

• Uncontrolled angina

• Ventricular arrhythmias

• Electrocardiographic evidence of acute ischemia or active conduction system abnormalities

• Cardiac amyloidosis

• No other cancer or treatment for cancer other than basal cell cancer of the skin within the past 5 years

• No poorly controlled chronic diseases (e.g., diabetes mellitus or hypertension)

• No HIV positivity

• No hepatitis B surface antigen or active hepatitis C infection

• No active systemic infection requiring therapy

• No serious medical or psychiatric illness that would interfere with study participation

PRIOR CONCURRENT THERAPY:

• No plasmapheresis within the past 4 weeks

• No major surgery within the past 4 weeks

• No prior bortezomib

• No chemotherapy (e.g., clarithromycin) within the past 4 weeks

• No radiotherapy within the past 3 weeks

• No corticosteroids (> 10 mg/day of prednisone or equivalent) within the past 3 weeks

• No other immunotherapy within the past 8 weeks

• No other investigational drugs within the past 14 days

• No concurrent participation in other clinical research studies